HEXABRIX 320 393 MG
IOXAGLATE MEGLUMINE : 393 MG IOXAGLATE SODIUM : 196 MG · DIN 00603740 · GUERBET
Health Canada status: CANCELLED POST MARKET
What is HEXABRIX 320?
HEXABRIX 320 393 MG contains IOXAGLATE MEGLUMINE : 393 MG IOXAGLATE SODIUM : 196 MG. It is listed in the Health Canada Drug Product Database under DIN 00603740, held by GUERBET, supplied as SOLUTION for INTRAVASCULAR administration. Health Canada currently lists it as cancelled post market, status dated 08-Jul-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HEXABRIX 320 used for?
Hexabrix 320: Angiography (cerebral, coronary, peripheral), CT enhancement, urography, arthrography. Hexabrix 200: Phlebography, intra-arterial DSA, and CT enhancement of the body.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00603740 |
|---|---|
| Brand name | HEXABRIX 320 |
| Generic / active ingredient | IOXAGLATE MEGLUMINE : 393 MG IOXAGLATE SODIUM : 196 MG |
| Manufacturer | GUERBET |
| Strength | 393 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVASCULAR |
| Schedule | Ethical |
| ATC code | V08AB03 IOXAGLIC ACID |
| AHFS class | 36:68.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 08-Jul-2015 |
| Original market date | 1983-12-31 00:00:00 |
How is it administered?
Varies by procedure. Administered intravascularly, intra-arterially, or by direct injection into structures (e.g., joint spaces, uterus). See specific procedure sections for detailed dosing.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text.
How is it supplied?
Not explicitly detailed in provided text (mentions use of glass or plastic syringes).
Contraindications
Contraindicated for myelography or any intrathecal procedure. Not for use in patients with severe hepatic and renal disease or hypersensitivity to salts of ioxaglic acid.
Warnings and precautions
Serious thromboembolic events (MI, stroke) reported. Risk of severe neurologic sequelae/paralysis. Risk of anuria in multiple myeloma. Caution in pheochromocytoma and sickle cell disease.
What can be used instead?
Other Canadian products sharing ATC code V08AB03 IOXAGLIC ACID. 0 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEXABRIX 200 | 123 MG | SOLUTION | GUERBET | CANCELLED POST MARKET | DIN 00788805 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.